USA - engelska - NLM (National Library of Medicine)

a-s medication solutions - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine hydrochloride in 5% dextrose injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risks of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine hy

Australien - engelska - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - verapamil hydrochloride, quantity: 5 mg - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - indications as at 17 jan 2005 : tachycardias, such as paroxysmal supraventricular tachycardia, atrial fibrillation with rapid ventricular response, (except in wpw syndrome, see "precautions"), atrial flutter with rapid conduction, extrasystoles. for the prophylaxis and/or therapy of ectopic arrhythmias (predominantly ventricular extrasystoles) in halothane anaesthesia and in the application of adrenaline in halothane anaesthesia, respectively. acute hypertension. acute coronary insufficiency.,tachycardias, such as paroxysmal supraventricular tachycardia, atrial fibrillation with rapid ventricular response, (except in wpw syndrome, see "precautions"), atrial flutter with rapid conduction, extrasystoles. for the prophylaxis and/or therapy of ectopic arrhythmias (predominantly ventricular extrasystoles) in halothane anaesthesia and in the application of adrenaline in halothane anaesthesia, respectively. acute hypertension. acute coronary insufficiency.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

bridgewest perth pharma pty ltd - potassium chloride, quantity: 750 mg - injection, concentrated - excipient ingredients: water for injections; potassium hydroxide; hydrochloric acid - indications as at august 2000: for the prevention and treatment of potassium deficiency (hypokalaemia). as an electrolyte supply. treatment of digitalis intoxication. these solutions are for use in patients who unable to take potassium orally. these solutions are for the preparation of dilute potassium chloride injections or for addition to intravenous fluids.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - tigecycline, quantity: 50 mg - injection, powder for - excipient ingredients: arginine; hydrochloric acid; sodium hydroxide - tigecycline juno is indicated for the treatment of the following infections in adults:,? complicated skin and skin structure infections, including those with methicillin resistant staphylococcus aureus (mrsa), where there is suspected or proven resistance to, intolerance of, or there are co- morbidities preventing the use of, other available agents.,? complicated intra-abdominal infections, where there is suspected or proven resistance to, intolerance of, or there are co-morbidities preventing the use of, other available agents.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - linezolid, quantity: 600 mg - injection, solution - excipient ingredients: glucose monohydrate; sodium citrate dihydrate; citric acid; hydrochloric acid; sodium hydroxide; water for injections - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species. linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - linezolid, quantity: 400 mg - injection, solution - excipient ingredients: glucose monohydrate; sodium citrate dihydrate; citric acid; hydrochloric acid; sodium hydroxide; water for injections - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species. linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

panpharma australia pty ltd - linezolid, quantity: 200 mg - injection, solution - excipient ingredients: glucose monohydrate; sodium citrate dihydrate; citric acid; hydrochloric acid; sodium hydroxide; water for injections - linezolid is indicated for the treatment of suspected or proven infections due to gram positive organisms resistant to multiple classes of antibiotics, including methicillin resistant staphylococcus species and vancomycin resistant enterococcus species. linezolid is active against gram-positive bacteria only. linezolid has no clinical activity against gram-negative pathogens. specific gram-negative therapy is required if a concomitant gram-negative pathogen is documented or suspected.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - sodium bicarbonate, quantity: 84 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections - sodium bicarbonate injection is indicated as an alkalinising agent in the treatment of metabolic acidosis which may occur in many conditions including diabetes, starvation, hepatitis, cardiac arrest, shock, severe dehydration, renal insufficiency, severe diarrhoea, addison's disease or administration of acidifying salts (e.g. excessive sodium chloride, calcium chloride, ammonium chloride). sodium bicarbonate injection is also used to increase urinary ph in order to increase the solubility of certain weak acids (e.g. cystine, sulphonamides, uric acid) and in the treatment of certain intoxications (e.g. methanol, phenobarbitone, salicylates, lithium) to decrease renal absorption of the drug or to correct acidosis.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - sodium bicarbonate, quantity: 84 mg/ml - injection, solution - excipient ingredients: disodium edetate; water for injections - sodium bicarbonate injection is indicated as an alkalinising agent in the treatment of metabolic acidosis which may occur in many conditions including diabetes, starvation, hepatitis, cardiac arrest, shock, severe dehydration, renal insufficiency, severe diarrhoea, addison's disease or administration of acidifying salts (e.g. excessive sodium chloride, calcium chloride, ammonium chloride). sodium bicarbonate injection is also used to increase urinary ph in order to increase the solubility of certain weak acids (e.g. cystine, sulphonamides, uric acid) and in the treatment of certain intoxications (e.g. methanol, phenobarbitone, salicylates, lithium) to decrease renal absorption of the drug or to correct acidosis.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - flucloxacillin, quantity: 500 mg - injection, powder for - excipient ingredients: - for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections. indications include pneumonia, osteomyelitis, skin and skin structure and wound infections, infected burns and cellulitis.